Physician profile
Linda Jaffe
NPI 1710046347
$3,250.24
in general payments reported to CMS, 2019-2025
20 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $311 · 2021: $99.30 · 2022: $216 · 2023: $410 · 2024: $1,379 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.74 | 2023-2025 | |
| Abbott Laboratories | $524.25 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $361.21 | 2024-2025 | Ultomiris, Soliris |
| Pfizer INC. | $241.41 | 2023-2025 | |
| Eisai INC. | $189.26 | 2023-2025 | |
| Nevro Corp. | $127.89 | 2022 | |
| Merz North America, INC. | $112.50 | 2019 | |
| Boston Scientific Corporation | $105.67 | 2025 | General - Pain Management |
| Allergan, INC. | $99.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $89.59 | 2024 | |
| Genentech USA, INC. | $76.95 | 2024 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $65.01 | 2023 | Vyvgart |
| Medtronic, INC. | $61.47 | 2023 | Percept Pc Brainsense |
| Teva Pharmaceuticals USA, INC. | $60.43 | 2024 | Ajovy, Austedo Xr |
| Biogen, INC. | $60.29 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $32.10 | 2024 | |
| Lundbeck LLC | $31.48 | 2024 | Vyepti |
| Amneal Pharmaceuticals LLC | $24.16 | 2025 | Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2025 | Hyqvia |
| Sk Life Science, INC. | $20.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.